- Home
- CZNC vs ATYR Comparison
CZNC vs ATYR Comparison
Compare CZNC & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CZNC | ATYR |
|---|---|---|
| Founded | 1864 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 377.9M | 79.2M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | CZNC | ATYR |
|---|---|---|
| Price | $21.47 | $0.73 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $22.00 | $8.75 |
| AVG Volume (30 Days) | 78.8K | ★ 2.2M |
| Earning Date | 01-22-2026 | 11-06-2025 |
| Dividend Yield | ★ 5.33% | N/A |
| EPS Growth | ★ 22.09 | N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | ★ $109,632,000.00 | $190,000.00 |
| Revenue This Year | $5.72 | N/A |
| Revenue Next Year | $7.18 | $18,728.88 |
| P/E Ratio | $11.98 | ★ N/A |
| Revenue Growth | ★ 7.59 | N/A |
| 52 Week Low | $17.85 | $0.64 |
| 52 Week High | $22.68 | $7.29 |
Technical Indicators
Market Signals| Indicator | CZNC | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 57.06 | 41.71 |
| Support Level | $21.76 | $0.70 |
| Resistance Level | $22.25 | $0.83 |
| Average True Range (ATR) | 0.48 | 0.05 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 50.93 | 26.75 |
Price Performance
Historical ComparisonAbout CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.